Show simple item record

dc.contributor.authorSewell, GJ
dc.contributor.authorRoberts, S
dc.date.accessioned2015-10-27T16:49:24Z
dc.date.available2015-10-27T16:49:24Z
dc.date.issued2003
dc.identifier.issn1078-1552
dc.identifier.issn1477-092X
dc.identifier.urihttp://hdl.handle.net/10026.1/3731
dc.description.abstract

<jats:p> Objective. The aim of this study was to determine the stability and compatibility of `high strength’ (50 mg/mL) and `normal strength’ (25 mg/mL) 5-fluorouracil (5-FU); the latter prepared from 50 mg/mL 5-FU in either 0.9% sodium chloride or 5% glucose diluents and filled into the Braun Easy-pumpÒ (also known as the Homepump Fresenius). Studies were conducted under storage (48C or 258C) and in-use (318C) conditions. </jats:p><jats:p> Methods. In the first study, the stability of 5-FU 50 mg/mL (undiluted) was determined in the EasypumpÒ at 258C and 318C over time intervals of 0, 1, 3, 5, 7, 14 and 21 days. In the second study, the stability of 25 mg/mL 5-FU diluted in 5% glucose and 0.9% sodium chloride for injection in the EasypumpÒ was determined after incubation at 48C for 0, 7 and 14 days and at 258C and 318C for 0, 1, 3, 5, 7, 14 and 21 days. For each time/temperature interval, the infusions were monitored for precipitation, colour change, pH, moisture loss, subvisual particulate levels (selected intervals) and chemical stability to assess for compatibility with the device. </jats:p><jats:p> Results. No significant changes in physical or chemical stability occurred in diluted solutions (25 mg/mL) over 14 days at 48C or 21 days at 258C and 318C or in the undiluted solutions (50 mg/mL) over 21 days at 258C and 318C, and 5-FU demonstrated suitable stability in the test devices. </jats:p>

dc.format.extent109-112
dc.languageen
dc.language.isoen
dc.publisherSAGE Publications
dc.titleStability and Compatibility of 5-fluorouracil infusions in the Braun Easypump
dc.typejournal-article
dc.typeArticle
plymouth.issue2-3
plymouth.volume9
plymouth.publication-statusPublished
plymouth.journalJournal of Oncology Pharmacy Practice
dc.identifier.doi10.1191/1078155203jp109oa
plymouth.organisational-group/Plymouth
plymouth.organisational-group/Plymouth/Faculty of Health
plymouth.organisational-group/Plymouth/REF 2021 Researchers by UoA
plymouth.organisational-group/Plymouth/REF 2021 Researchers by UoA/UoA03 Allied Health Professions, Dentistry, Nursing and Pharmacy
plymouth.organisational-group/Plymouth/REF 2021 Researchers by UoA/UoA03 Allied Health Professions, Dentistry, Nursing and Pharmacy/UoA03 Allied Health Professions, Dentistry, Nursing and Pharmacy MANUAL
plymouth.organisational-group/Plymouth/Research Groups
plymouth.organisational-group/Plymouth/Research Groups/Institute of Health and Community
plymouth.organisational-group/Plymouth/Users by role
dc.identifier.eissn1477-092X
dc.rights.embargoperiodNot known
rioxxterms.versionofrecord10.1191/1078155203jp109oa
rioxxterms.licenseref.urihttp://www.rioxx.net/licenses/all-rights-reserved
rioxxterms.typeJournal Article/Review


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record


All items in PEARL are protected by copyright law.
Author manuscripts deposited to comply with open access mandates are made available in accordance with publisher policies. Please cite only the published version using the details provided on the item record or document. In the absence of an open licence (e.g. Creative Commons), permissions for further reuse of content should be sought from the publisher or author.
Theme by 
Atmire NV